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In the present study, we found that ZBTB20, a member of the POK (POZ and Krüppel) family of tran-
scriptional repressors, was signiﬁcantly up-regulated in lung cancer tissues, compared with adjacent
normal tissues. Our in vitro studies further found that ZBTB20 overexpression promoted, while its
inhibition using small interfering RNA suppressed cell proliferation. Consistently, key regulators
in cell-cycle progression, such as Cyclin D1, Cyclin E, P21 and P27, were also regulated by ZBTB20.
At the molecular level, we further revealed that FoxO1, a tumor suppressor in multiple human can-
cers, was transcriptionally repressed by ZBTB20. Therefore, our results highlight an important role
for ZBTB20 in controlling NSCLC development, which might be helpful to identify potential thera-
peutic targets for its treatment.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Non-small cell lung cancer (NSCLC), including adenocarcinoma,
squamous cell carcinoma and large cell carcinoma, represents
approximately 85–90% of lung cancer diagnoses [1]. Despite
numerous reports on NSCLC genomics and advancements in the
survival rate of patients in recent years [2], its molecular determi-
nants underlying cancer initiation and (or) progression remains
poorly understood.
Zinc ﬁnger and BTB domain-containing 20 (ZBTB20), containing
an intact N-terminal BTB domain and a C-terminal zinc ﬁnger
domain, is a new member of the POK (POZ and Krüppel) family of
transcriptional repressors [3,4]. Initially studies using genetic mod-
els demonstrated that ZBTB20 was required for postnatal survival
and glucose homeostasis [5]. Besides, ZBTB20 was preferentially
expressed by hippocampal progenitors, suggesting it may play a
role in the developing hippocampus [6]. In addition, ZBTB20 pro-
moted toll-like receptor-triggered production of proinﬂammatory
cytokines by repressing IjBa gene transcription [7]. Recent studies
also demonstrated that ZBTB20 was involved in the tumorigenesis.
For instance, its expression was increased in hepatocellular carci-
noma (HCC) and might be an independent prognostic factor for
HCC [8]. However, Weng et al. reported that ZBTB20was down-reg-
ulated following 70% hepatectomy in mice, suggesting that ZBTB20may inhibit cell proliferation in the hepatocytes [9]. Although the
inconsistence remains unknown now, the roles of ZBTB20 could
be cell- or tissue-speciﬁc. On the other hand, the functions of
ZBTB20 may be different between normal and cancer cells. Besides,
a genome-wide association study identiﬁed that a single-nucleo-
tide polymorphism (SNP) (rs9841504) in ZBTB20 gene was associ-
ated with non-cardia gastric cancer susceptibility in the Han
Chinese population [10]. However, whether ZBTB20 participates
in the NSCLC progression remains uncharacterized.
In the present study, we found a marked increase of ZBTB20
expression in NSCLC tissues. Its biological functions and mecha-
nisms in the NSCLC progression were further investigated.
2. Material and methods
2.1. Tissue samples
25 paired primary NSCLC tissues and adjacent normal tissues
were collected from routine therapeutic surgery at our depart-
ment. All samples were obtained with informed consent and
approved by Board of Reviewers from Shengjing Hospital of China
Medical University.
2.2. Cell culture and reagents
NSCLC cell lines (A549 and NCI-H1650) were purchased from
The Cell Bank of Type Culture Collection of Chinese Academy of
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Eagle’s medium (DMEM, Gibco, Shanghai, China) supplemented
with 10% fetal calf serum (Gibco), and 1% penicillin/streptomycin
(Gibco). Cultures were maintained at 37 C in a humidiﬁed atmo-
sphere with 5% CO2. TNFa and IL-1b were obtained from Sigma–
Aldrich Company (USA).
2.3. BrdU and cell-cycle assays
A cell proliferation enzyme-linked immunosorbent assay (BrdU
kit; Beyotime) was used to analyze the incorporation of BrdU dur-
ing DNA synthesis following the manufacturer’s protocols. Absor-
bance was measured at 450 nm in the Spectra Max 190 ELISA
reader (Molecular Devices, Sunnyvale, CA). For cell-cycle analysis,
cells were collected, rinsed and ﬁxed in 75% cold ethanol at
20 C overnight. Then, cells were treated with 100 lg/mL RNase
A in Tris–HCl buffer (pH 7.4) and then stained with 25 lg/mL pro-
pidium iodide (PI) (BD Biosciences, CA). Cell cycle distribution was
determined by ﬂow cytometry (Becton Dickinson, CA). 10000 cells
were acquired and analyzed for DNA content. All data were col-
lected, stored, and analyzed by ModFit software. Histograms repre-
sent the percentage of cells in each phase of the cell cycle (G0/G1, S
and G2/M).
2.4. Small interfering RNA, RNA extraction and real-time analysis
To knockdown endogenous expression of ZBTB20, cells were
seeded into 6-well plates and transfected with 20 nM non-target-
ing siRNA, and ZBTB20 siRNA oligos (Genepharm, Shanghai, China).
The sequences of ZBTB20 siRNA oligos and negative controls (NC)
are listed as following: ZBTB20 (50-CUAUGCGAUUACGACUAAGU-
30); NC (50-UUAGCAGUAUGGCAUACUAG-30). Total RNAs were iso-
lated from tissues or cells by TRIzol reagent (Invitrogen), and
reverse transcriptions were performed by Takara RNA PCR kit
(Takara, China), following the manufacturer’s protocols. In order
to determine the transcripts of the interest genes, real-time PCR
was performed using a SYBR Green Premix Ex Taq (Roche, Switzer-
land) on Light Cycler 480 (Roche). 36B4 gene was used as an inter-
nal control.
2.5. Western blot
Cells or tissues were harvested by homogenization and sonica-
tion using ice-cold lysis buffer containing 50 mM Tris–HCl, pH 7.0,
100 mM 2-ME, 2% w/v SDS and 10% glycerol. After centrifugation at
12000g for 10 min at 4 C, proteins in the supernatants were
quantiﬁed and separated by 10% SDS PAGE, transferred to nitrocel-
lulose membrane (Amersham Bioscience, Buckinghamshire, UK).
After blocking with 10% non-fat milk, membranes were immuno-
blotted with antibodies, followed by HRP-linked secondary anti-
bodies (Cell Signaling, USA). The signals were detected by
visualized with a Typhoon PhosphorImager (Amersham Biosci-
ences), according to manufacturer’s instructions. Anti-ZBTB20,
FoxO1 and FoxO3 antibodies were obtained from Abcam Company
(USA). Anti-Cyclin D1, -Cyclin E, -P21, -P27 and GAPDH antibodies
were from CellSignaling Technology (USA).
2.6. Luciferase reporter assays
FoxO1 promoter from 1000 bp to +10 bp was cloned and
inserted into pGL3 vector (Promega, Madison, Wisconsin, USA).
For luciferase reporter assays, A549 cells were seeded into 24-well
plates and transfected with 100 ng promoter plasmids by Lipofect-
amine 2000 (Invitrogen, Shanghai, China), according to the manu-facturer’s instructions. 50 ng pRL-TK plasmids (Promega)
expressing renilla luciferase was used to normalize the luciferase
activities, which were measured using the Dual Luciferase Reporter
Assay System (Promega).
2.7. ChIP assays
Chromatin immunoprecipitation (ChIP) assay kits were used
(Millipore, Billerica, Massachusetts, USA). In short, A549 cells were
ﬁxed with 1% formaldehyde to cross-link the proteins and DNA.
DNA was sheared to fragments at 200–1000 bp using several son-
ication. The chromatin was then incubated and precipitated with
ZBTB20 or IgG antibodies. The immunoprecipitated DNA fragments
were detected by PCR and quantiﬁed by real-time PCR. The primer
sequences are listed as following: region from 200 bp to 100 bp
(Forward: 50-GACCTACAGTTAGCGATTAG-30; Reverse: 50-CTAGCA-
TAGGATCAGTTACTA-30); region from 2000 bp to 1800 bp (For-
ward: 50-ATTAGCAGCATAGCGGCATGGA-30; Reverse: 50-TTAGGA
CATGCAGTCTGACGCC-30).
2.8. Statistical analysis
All the cellular experiments were performed at least three
times. Data are presented as mean ± S.E.M. Statistical analysis were
conducted by Student’s t test or ANOVA using StatView software
(Abacus Concepts, Berkeley, CA). Statistical signiﬁcance is
displayed as ⁄ (P < 0.05), ⁄⁄ (P < 0.01) or ⁄⁄⁄ (P < 0.001).3. Results
3.1. Up-regulation of ZBTB20 in NSCLC tissues
Firstly, ZBTB20 mRNA levels were measured in 25 paired NSCLC
tissues and adjacent normal tissues by quantitative real-time PCR
analysis. As shown in the Fig. 1A, ZBTB20 mRNA levels were signif-
icantly up-regulated in NSCLC tissues (Fig. 1A). In addition, Wes-
tern blot analysis also conﬁrmed the increased protein
abundance of ZBTB20 in NSCLC tissues (Fig. 1B). To exclude the
possibility that the ZBTB20 is dys-regulated by immune cells, lung
cancer cells were puriﬁed according to a previous study [11]. As
shown in the Supplementary Fig. 1A, ZBTB20 expression was about
6-fold higher in cancer cells, compared with that in immune cells.
Besides, ZBTB20 were signiﬁcantly up-regulated in cancer cells,
compared with that in normal cells (Supplementary Fig. 1A and
B). However, its expression in immune cells between two groups
remained unaffected (Supplementary Fig. 1A and B).
Next, we aim to identify a potential mechanism for the up-reg-
ulation of ZBTB20 in NSCLC tissues. It has been well-known that
inﬂammatory signaling was usually activated in NSCLC tissues to
promote tumorigenesis [12,13]. Indeed, we observed an increased
mRNA levels of pro-inﬂammatory cytokines, such as TNFa and IL-
1b, in NSCLC tissues (Fig. 1C). As shown in Fig. 1D and E, treatment
of these two cytokines enhanced ZBTB20 expression signiﬁcantly
in A549 cells. Therefore, our results demonstrate the involvement
of pro-inﬂammatory cytokines in the up-regulation of ZBTB20 in
NSCLC tissues.
3.2. ZBTB20 promotes cell proliferation in lung cancer cells
To determine the functional signiﬁcance of ZBTB20, retro-
viruses containing empty vector (EV) or ZBTB20 were prepared
and administrated into A549 cells (Fig. 2A). As a result, ZBTB20
overexpression resulted in a signiﬁcant increase in cell number
Fig. 1. Up-regulation of ZBTB20 in NSCLC tissues. (A and B) mRNA and representative protein levels of ZBTB20 were analyzed by real-time PCR (A) and Western blot (B) in
NSCLC or adjacent normal tissues, n = 25. (C) mRNA levels of TNFa and IL-1b in NSCLC or adjacent normal tissues. (D and E) mRNA and representative protein levels of ZBTB20
were analyzed by real-time PCR (D) and Western blot (E) in A549 cells treated with TNFa (10 ng/ml), IL-1b (5 ng/ml) or vehicle control (PBS) for 12 or 24 h, respectively.
Fig. 2. Roles of ZBTB20 on lung cancer cell proliferation. (A) ZBTB20 expression was determined by Western blot in A549 cells transfected with empty vector (EV) or ZBTB20
for 36 h. (B) The growth curve of A549 cells transfected with empty vector (EV) or ZBTB20. (C) The cell proliferative potential (BrdU) was determined in A549 cells transfected
with empty vector (EV) or ZBTB20 for 36 h. (D) ZBTB20 expression was determined by Western blot in A549 cells transfected with siRNA oligos targeting ZBTB20 or negative
controls (NC) for 36 h. (E) The growth curve of A549 cells transfected with transfected with siRNA oligos targeting ZBTB20 or negative controls (NC). (F) The cell proliferative
potential (BrdU) was determined in A549 cells transfected with siRNA oligos targeting ZBTB20 or negative controls (NC) for 36 h.
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analysis (Fig. 2C). Next, small interfering RNA (siRNA) was
employed to knockdown endogenous ZBTB20 expression in A549
cells (Fig. 2D). As expected, ZBTB20 deﬁciency led to a marked
decrease in cell number and reduced proliferation (Fig. 2E and F).
Moreover, similar results were also obtained in NCI-H1650 cells
(Supplementary Fig. 2A–F).3.3. ZBTB20 affects expression of the cell-cycle regulators
Next, we examined whether ZBTB20 could regulate cell-cycle
progression. As shown in the Fig. 3A, ZBTB20 overexpressing cells
had a signiﬁcantly reduced percentage of cells in the G1/G0 phase
and increased percentage of cells in the S phase, compared to EV-
transfected cells (Fig. 3A). Cyclin D1 and Cyclin E are two members
Fig. 3. ZBTB20 modulates the expression of cell-cycle regulators in A549 cells. (A) The cell-cycle phase of A549 cells were analyzed by ﬂow cytometry after transfection with
empty vector (EV) or ZBTB20 for 36 h. (B and C) mRNA and protein levels of Cyclin D1, Cyclin E, P21 and P27 were determined by real-time PCR (B) and Western blot (C) in
A549 cells transfected with empty vector (EV) or ZBTB20 for 24 or 36 h, respectively. (D and E) mRNA (D) and protein (E) levels of Cyclin D1, Cyclin E, P21 and P27 in A549
cells transfected with siRNA oligos targeting ZBTB20 or negative controls (NC) for 24 or 36 h, respectively.
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cell-cycle progression, while p21 and p27 are known as cyclin-
dependent kinase inhibitors. Here, we found that expression of
Cyclin D1 and Cyclin E were up-regulated while p21 and p27 levels
were down-regulated in A549 cells overexpressing ZBTB20 (Fig. 3B
and C). In agreement, knockdown of ZBTB20 reduced Cyclin D1 and
Cyclin E expression while increased p21 and p27 expression in
A549 cells (Fig. 3D and E).
3.4. ZBTB20 represses FoxO1 expression in lung cancer cells
Previous studies have shown that those cell-cycle regulators
above mentioned were tightly regulated by several tumor suppres-
sors and oncogenes, such as FoxO1, P53, Stat3, E2F1, b-Catenin and
c-myc [14–19]. As shown in Fig. 4A, only FoxO1 was signiﬁcantly
down-regulated by ZBTB20 overexpression (Fig. 4A), which was
further conﬁrmed by Western blot analysis (Fig. 4B). Moreover,
knockdown of ZBTB20 increased mRNA and protein levels of FoxO1
(Fig. 4C and D). In our experiments, the majority of endogenous
FoxO1 protein localized in the cytoplasm (Supplementary
Fig. 3A), which is consistent with a previous report [20]. The neg-
ative regulation of FoxO1 by ZBTB20 was also observed in NCI-
H1650 cells (Supplementary Fig. 3B–E). In addition, expression lev-
els of FoxO3, another member of FoxO transcription factors, were
not affected by ZBTB20 overexpression or knockdown (Supplemen-
tary Fig. 4A–D).
Consistent with the negative regulation of FoxO1 by ZBTB20,
mRNA levels of FoxO1 were signiﬁcantly decreased in NSCLC tis-
sues, compared with adjacent normal tissues (Fig. 4E). Moreover,
a negative correlation between mRNA levels of ZBTB20 and FoxO1
was also observed (Fig. 4F), suggesting that FoxO1 represents a
transcriptional target of ZBTB20 in NSCLC.3.5. The human FoxO1 gene promoter is a transcriptional target of
ZBTB20
To delineate the mechanism of this regulation, the promoter
region of human FoxO1 gene from 1000 bp to +10 bp was cloned
and inserted into luciferase reporter vectors. In accordance with
the down-regulation of FoxO1, ZBTB20 exerted up to a threefold
repression of the reporter FoxO1-1000Luc in a dose-dependent
manner (Fig. 5A). Then, a serial deletion of this promoter was per-
formed, to further identify the potential region mediating tran-
scriptional suppression by ZBTB20. As shown in the Fig. 5B,
deletion of 200 bp to 100 bp region largely impaired the inhib-
itory effects of ZBTB20 on the FoxO1 reporters, indicating that the
ZBTB20-responsive element may be located in the +200 bp to
100 bp region of the FoxO1 promoter (Fig. 5B). In addition, chro-
matin immunoprecipitation (ChIP) assays also conﬁrmed that
ZBTB20 was able to bind with this region in A549 cells (Fig. 5C).
Notably, this association of ZBTB20 with the FoxO1 promoter
was substantially increased in NSCLC tissues (Fig. 5D).
3.6. FoxO1 overexpression or knockdown attenuated the proliferative
roles of ZBTB20
Finally, to establish the functional connection between ZBTB20
and FoxO1, A549 cells were transduced with FoxO1 expression
plasmids or empty vector (EV) after transfection of ZBTB20
(Fig. 6A). As shown in Fig. 6B and C, FoxO1 re-introduction reversed
the proliferative roles of ZBTB20. Besides, endogenous FoxO1 was
depleted by small interfering RNA oligos (Fig. 6D). As expected,
FoxO1 deﬁciency resulted in an increase of cell proliferation and
dys-regulated expression of cell-cycle regulators (Fig. 6E and F).
Notably, ZBTB20 overexpression could not further regulate cell
Fig. 4. ZBTB20 represses FoxO1 expression. (A and B) mRNA and protein levels of FoxO1, P53, Stat3, E2F1, b-Catenin and C-myc were analyzed by real-time PCR (A) and
Western blot (B) in A549 cells transfected with empty vector (EV) or ZBTB20 for 24 or 36 h, respectively. (C and D) mRNA and protein levels of FoxO1 were analyzed by real-
time PCR (C) and Western blot (D) in A549 cells transfected with siRNA oligos targeting ZBTB20 or negative controls (NC) for 24 or 36 h, respectively. (E) mRNA levels of
FoxO1 were analyzed by real-time PCR in NSCLC tissues or adjacent normal tissues, n = 25. (F) Pearson correlation of mRNA levels of ZBTB20 and FoxO1 in NSCLC tissues or
adjacent normal tissues, n = 25.
Fig. 5. ZBTB20 transcriptionally regulates FoxO1 promoter activity. (A) Construction and luciferase reporter analysis of human FoxO1 promoter. The promoter region from
1000 to +10 bp was cloned and co-transfected with ZBTB20 expression plasmids in A549 cells for 36 h. The transcription start site was set as +1 bp. (B) Transcriptional
activity of human FoxO1 promoter by series of deletion. A549 cells were transfected with the indicated plasmids for 36 h. (C) ChIP assays to show the recruitment of ZBTB20
onto FoxO1 promoter. The promoter region from 2000 to 1800 bp was set as a negative control. Real-time PCR was performed to quantify the binding. A549 cells were
cultured for 48 h after seeding and then subjected to ChIP assays. (D) ChIP analysis of ZBTB20 binding to the FoxO1 promoter in normal or NSCLC tissues, n = 10.
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depletion of FoxO1 (Fig. 6E and F), suggesting that the oncogenic
role of ZBTB20 in the NSCLC progression, at least in part, depends
on its down-regulation of FoxO1.4. Discussion
Our present study, for the ﬁrst time, showed the aberrant
expression of ZBTB20 in NSCLC tissues. With regard to the factors
Fig. 6. FoxO1 re-introduction or knockdown attenuates the proliferative roles of ZBTB20. Protein level of FoxO1 was determined by Western blot in A549 cells transfected
with the indicated plasmids for 36 h. (B and C) The growth curve and cell proliferative potential (BrdU) were determined in A549 cells transfected with ZBTB20, FoxO1 and
ZBTB20 plus FoxO1. (D) Protein level of FoxO1 was determined by Western blot in A549 cells transfected with the indicated plasmids or siRNA oligos for 36 h. (E and F) The
cell proliferative potential (F) and mRNA levels of cell-cycle regulators (G) were determined in A549 cells transfected with the indicated plasmids or siRNA oligos.
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inﬂammatory cytokines could increase ZBTB20 expression. Inter-
estingly, a recent study revealed that hypermethylation in the
ZBTB20 gene was associated with neuro-psychiatric diseases
[21]. Therefore, whether epigenetic regulation could also be
involved in the up-regulation of ZBTB20 in NSCLC needs to be fur-
ther investigated.
To test the role of ZBTB20 in NSCLC development, gain- and
loss-of-function approaches were performed. ZBTB20 overexpres-
sion promoted cell proliferation coincident with the signiﬁcant
progression of cell-cycle. Consistently, ablation of ZBTB20 expres-
sion resulted in a reduced cell proliferation. Additionally, expres-
sion of key regulators in the cell-cycle, including Cyclin D1,
Cyclin E, p21 and p27, were affected by ZBTB20 overexpression
or knockdown. Together, these data indicate that ZBTB20 enhances
NSCLC progression through promotion of cell proliferation and
cell-cycle entry. However, whether ZBTB20 could regulate cell
apoptosis and metastasis remains to be deﬁned.
At the molecular level, we demonstrated that ZBTB20 could
repress FoxO1 expression through directly bound to its proximal
promote region. It has been well-established that FoxO1 could
inhibit cell-cycle progression through up-regulation of p27 and
p21, and down-regulation of Cyclin D1 [22]. As FoxO1 plays a
critical role in cell fate decision, mounting reports indicate that
FoxO1 functions as a tumor suppressor in a variety of human can-
cers [23]. Indeed, FoxO1 expression was identiﬁed as a favorable
prognostic factor in NSCLC [20]. On the other hand, the anti-can-
cer activity of FoxO1 was regulated at multiple levels including
phosphorylation, acetylation, ubiquitination and protein–protein
interactions [23,24]. Despite the importance of FoxO1 in regula-
tion of tumorigenesis, it remains a improper candidate as a drug
target due to the lack of a ligand-binding domain. Thus, a betterunderstanding of its regulatory axis might provide new opportu-
nities for developing more effective therapeutic approaches to
treat cancers. In addition, we found that FoxO3, also known as
a tumor suppressor, was not affected by ZBTB20 overexpression
or knockdown, suggesting a speciﬁc regulatory role of ZBTB20
in the repression of FoxO1. Moreover, additional experiments,
such as recruitment of transcriptional co-repressors or histone
modiﬁcations, are still needed to further clarify the mechanisms
of this transcriptional regulation. Deciphering this pathway in
greater detail might be helpful to identify unique therapeutical
targets for cancer intervention.
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